Bks Advisors Lowers stake in Rockwell Medical Inc (RMTI)

Rockwell Medical Inc (RMTI) : Bks Advisors reduced its stake in Rockwell Medical Inc by 1.98% during the most recent quarter end. The investment management company now holds a total of 247,458 shares of Rockwell Medical Inc which is valued at $1,781,698 after selling 5,000 shares in Rockwell Medical Inc , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Rockwell Medical Inc makes up approximately 0.87% of Bks Advisors’s portfolio.

Other Hedge Funds, Including , Benchmark Capital Advisors reduced its stake in RMTI by selling 2,400 shares or 7.89% in the most recent quarter. The Hedge Fund company now holds 28,000 shares of RMTI which is valued at $210,280. Rockwell Medical Inc makes up approx 0.17% of Benchmark Capital Advisors’s portfolio.Interocean Capital boosted its stake in RMTI in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 19,165 shares of Rockwell Medical Inc which is valued at $152,170. Rockwell Medical Inc makes up approx 0.04% of Interocean Capital’s portfolio.California State Teachers Retirement System reduced its stake in RMTI by selling 5,992 shares or 5.63% in the most recent quarter. The Hedge Fund company now holds 100,477 shares of RMTI which is valued at $778,697. Fox Run Management L.l.c. added RMTI to its portfolio by purchasing 31,200 company shares during the most recent quarter which is valued at $248,976. Rockwell Medical Inc makes up approx 0.12% of Fox Run Management L.l.c.’s portfolio.

Rockwell Medical Inc closed down -0.09 points or -1.23% at $7.23 with 2,50,187 shares getting traded on Wednesday. Post opening the session at $7.31, the shares hit an intraday low of $7.07 and an intraday high of $7.4 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Rockwell Medical Inc reported $-0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.07. The company had revenue of $12.50 million for the quarter, compared to analysts expectations of $13.85 million. The company’s revenue was down -3.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.05 EPS.

Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Rockwell Medical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Rockwell Medical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.